What is the recommended intravenous amiodarone dosing regimen for rate control or rhythm conversion in atrial fibrillation in an adult without weight or organ‑function limitations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 18, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Intravenous Amiodarone Dosing for Atrial Fibrillation

Standard Loading Protocol

For rate control or rhythm conversion in atrial fibrillation, administer amiodarone as a 150 mg IV bolus over 10 minutes, followed by 1 mg/min for 6 hours (360 mg), then 0.5 mg/min for 18 hours (540 mg), with a maximum total dose of 2.2 g over 24 hours. 1

Initial Bolus

  • Give 150 mg IV over 10 minutes as the loading bolus 1
  • This initial dose begins rate control, which typically occurs after the first 300–400 mg 2

Maintenance Infusion

  • Early maintenance: 1 mg/min for 6 hours (total 360 mg) 1
  • Late maintenance: 0.5 mg/min for 18 hours (total 540 mg) 1
  • Total 24-hour dose should not exceed 2.2 g 1

Expected Clinical Response

Rate Control

  • Ventricular rate reduction is the most immediate and predictable response 2
  • Rate control generally occurs after the first 300–400 mg 2
  • In patients with rapid ventricular rates (>135 bpm), heart rate decreases to approximately 104 bpm at 30 minutes and 94 bpm at 60 minutes 3

Rhythm Conversion

  • Cardioversion to sinus rhythm occurs in 34–69% with bolus-only regimens and 55–95% with bolus plus continuous infusion 1, 4
  • Most conversions occur after 6–8 hours of therapy and often require ≥1000 mg total dose 1, 4
  • Conversion rates are 28% at 30 minutes and 42% at 60 minutes with high-dose bolus regimens 3
  • Higher doses (>1500 mg/day) are superior to placebo for cardioversion 4

Critical Monitoring Requirements

During Infusion

  • Continuous cardiac monitoring throughout the infusion period 1
  • Blood pressure monitoring for hypotension (occurs in 16% of patients) 1
  • Watch for bradycardia (occurs in 4.9% with IV therapy) and atrioventricular block 1
  • Monitor QT interval for excessive prolongation 1

Common Pitfalls

  • Asymptomatic hypotension may occur, particularly with bolus dosing 3
  • Symptomatic bradycardia requiring intervention occurs in approximately 4% of patients 5
  • Superficial phlebitis at the infusion site can develop; consider central access for prolonged infusions 3

Special Clinical Considerations

Structural Heart Disease

  • Amiodarone is the preferred agent in patients with heart failure or reduced ejection fraction, where class IC drugs are contraindicated 1, 4
  • It is relatively safe in patients with left ventricular dysfunction 4

Renal Impairment

  • No dose adjustment needed for renal dysfunction, as amiodarone undergoes hepatic metabolism, not renal excretion 1

Contraindications

  • Amiodarone is relatively contraindicated in patients with significant lung disease; if no alternative exists, use the lowest effective dose and shortest duration possible 1

Drug Interactions Requiring Immediate Attention

  • Warfarin: Reduce dose by 30–50% and check INR within 3–5 days, as amiodarone significantly increases INR 6, 1
  • Digoxin: Reduce dose by 50% immediately, as amiodarone doubles digoxin levels 6, 1
  • Statins: Dose adjustments necessary due to cytochrome P450 inhibition 1
  • Avoid coadministration with other QT-prolonging medications without expert consultation 1, 7

Transition to Oral Therapy

When to Begin Oral Loading

  • Start oral amiodarone at 600–800 mg daily in divided doses while continuing the IV infusion at 0.5 mg/min after approximately 8 hours of IV therapy 6
  • Continue oral loading until a cumulative dose of approximately 10 g is reached (typically 1–2 weeks) 6, 1

Maintenance Dosing

  • After completing the 10-g oral load, reduce to 200–400 mg daily for atrial fibrillation 6, 1
  • Some patients may require as low as 100–200 mg daily for maintenance 7

References

Guideline

Amiodarone Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Intravenous Amiodarone in the Management of Atrial Fibrillation.

Journal of cardiovascular pharmacology and therapeutics, 1999

Guideline

Amiodarone Oral to Intravenous Equivalency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Amiodarone Loading Dose Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the repeat dose timing for IV amiodarone in unstable AF and what other rate control strategies are used?
What is the recommended dose of intravenous (IV) Amiodarone for an adult patient presenting with atrial fibrillation in an emergency setting?
What is the recommended Amiodarone (antiarrhythmic agent) bolus dose for a patient with arrhythmia?
What is the recommended dosage of amiodarone (antiarrhythmic medication) after electrical cardioversion?
What is the recommended loading dose of amiodarone (antiarrhythmic medication)?
Should primary closure be performed for a Grade 3 (deep, heavily contaminated) dog bite wound?
In a pregnant woman with cystic fibrosis (F508del mutation), should Trikafta (elexacaftor/tezacaftor/ivacaftor) be continued or discontinued?
What is the appropriate diagnostic testing and first‑line therapy for an overweight adult suspected of obstructive sleep apnea (OSA) with neck circumference >17 in (43 cm) in men or >16 in (41 cm) in women, loud snoring, witnessed apneas, nocturnal choking, and Epworth Sleepiness Scale ≥10?
For a cystic fibrosis patient aged ≥12 years with at least one F508del mutation, what is the recommended dosing of Trikafta (elexacaftor/tezacaftor/ivacaftor), required monitoring of liver function tests (alanine aminotransferase, aspartate aminotransferase, bilirubin), contraindicated cytochrome P450 3A (CYP3A) inducers, and precautions such as cataract screening and use in hepatic impairment?
What is the appropriate dosing, indications, and safety monitoring for Trikafta (elexacaftor/tezacaftor/ivacaftor) in a cystic fibrosis patient aged ≥12 years with at least one F508del mutation?
In a child aged ≥10 years and weighing >30 kg, what are the recommended doses, dosing intervals, maximum daily limits for mefenamic acid and paracetamol, and how should the two drugs be timed when given together?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.